This is the authors' abstract. We don't add key points for this paper.
Modified-release (MR) formulations improve adherence and therapeutic consistency by controlling drug release; however, prolonged, formulation-dependent absorption produces complex, multiphasic pharmacokinetics that complicate dose selection, bioequivalence assessment, and clinical optimization. Pharmacometrics, integrating population pharmacokinetics (PopPK), physiologically based pharmacokinetics (PBPK), and pharmacokinetic-pharmacodynamic (PK/PD) modeling, provides a quantitative framework for characterizing formulation-controlled inputs, distinguishing absorption from disposition processes, and quantifying interindividual variability across oral, transdermal, and long-acting injectable (LAI) platforms. Within drug development, model-informed drug development (MIDD) applies PBPK models to link in vitro release and physiology with systemic exposure, enabling mechanistic prediction of food effects, organ impairment, and drug–drug interactions, while PopPK models identify variability drivers and define population-based initial dosing regimens that inform labeling. Formulation optimization and virtual bioequivalence are achieved by simulating alternative release profiles and exposure metrics against predefined regulatory criteria, enabling prospective evaluation of scenarios beyond feasible clinical testing. MIDD and model-informed precision dosing (MIPD) represent distinct but sequential stages along a translational continuum: MIDD establishes evidence-based population dosing strategies during development, whereas MIPD operationalizes validated PopPK/PBPK models as Bayesian priors, integrates patient-specific therapeutic drug monitoring data, and individualizes dosing in real time. Emerging hybrid PBPK-PopPK frameworks, machine learning (ML)-assisted covariate discovery, and tissue-aware digital twins further enhance predictive performance. Collectively, these pharmacometric approaches provide a translational bridge linking MR formulation design, regulatory evaluation, and individualized therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rasool et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: